Alfacyte was established in 2012 by Prof. William Stimson, Professor of Immunology at The University of Strathclyde in Glasgow, Scotland. Alfacyte's patented platform technology has the ability to steer T-cell response. When applied to allergy, it has the ability to boost immune response and increase tolerance to allergens.
Alfacyte is currently researching the immunological properties of a number of candidate molecules which will form the backbone for the development of new therapeutics. The initial application area is in the field of food allergy - specifically peanuts. Further research will prove the platform's immune-modulating characteristics which will offer new prospects in fields such as oncology vaccination.